Literature DB >> 28089680

Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by the Age-Related Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research Group.

Amitha Domalpally1, Traci E Clemons2, Ronald P Danis1, SriniVas R Sadda3, Catherine A Cukras4, Cynthia A Toth5, Thomas R Friberg6, Emily Y Chew7.   

Abstract

PURPOSE: To compare rates of peripheral retinal changes in Age-Related Eye Disease Study 2 (AREDS2) participants with at least intermediate age-related macular degeneration (AMD) with control subjects without intermediate age-related changes (large drusen).
DESIGN: Cross-sectional evaluation of clinic-based patients enrolled in AREDS2 and a prospective study. PARTICIPANTS: Participants from prospective studies.
METHODS: The 200° pseudocolor and fundus autofluorescence (FAF) images were captured on the Optos 200 Tx Ultrawide-field device (Optos, Dunfermline, Scotland) by centering on the fovea and then steering superiorly and inferiorly. The montaged images were graded at a reading center with the images divided into 3 zones (zone 1 [posterior pole], zone 2 [midperiphery], and zone 3 [far periphery]) to document the presence of peripheral lesions. MAIN OUTCOME MEASURES: Peripheral retinal lesions: drusen, hypopigmentary/hyperpigmentary changes, reticular pseudodrusen, senile reticular pigmentary changes, cobblestone degeneration, and FAF abnormalities.
RESULTS: A total of 484 (951 eyes) AREDS2 participants with AMD (cases) and 89 (163 eyes) controls without AMD had gradable color and FAF images. In zones 2 and 3, neovascularization and geographic atrophy (GA) were present, ranging from 0.4% to 6% in eyes of cases, respectively, and GA was present in 1% of eyes of controls. Drusen were detected in 97%, 78%, and 64% of eyes of cases and 48%, 21%, and 9% of eyes of controls in zones 2 and 3 superior and 3 inferior, respectively (P < 0.001 for all). Peripheral reticular pseudodrusen were seen in 15%. Senile reticular pigmentary change was the predominant peripheral change seen in 48% of cases and 16% of controls in zone 2 (P < 0.001). Nonreticular pigment changes were less frequent in the periphery than in the posterior pole (46% vs. 76%) and negligible in controls.
CONCLUSIONS: Peripheral retinal changes are more prevalent in eyes with AMD than in control eyes. Drusen are seen in a majority of eyes with AMD in both the mid and far periphery, whereas pigment changes and features of advanced AMD are less frequent. Age-related macular degeneration may be more than a "macular" condition but one that involves the entire retina. Future longitudinal studies of peripheral changes in AMD and their impact on visual function may contribute to understanding AMD pathogenesis. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28089680     DOI: 10.1016/j.ophtha.2016.12.004

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  26 in total

1.  Peripheral Retinal Imaging Biomarkers for Alzheimer's Disease: A Pilot Study.

Authors:  Lajos Csincsik; Thomas J MacGillivray; Erin Flynn; Enrico Pellegrini; Giorgos Papanastasiou; Neda Barzegar-Befroei; Adrienne Csutak; Alan C Bird; Craig W Ritchie; Tunde Peto; Imre Lengyel
Journal:  Ophthalmic Res       Date:  2018-04-05       Impact factor: 2.892

2.  Increased serum proteins in non-exudative AMD retinas.

Authors:  Hannah Schultz; Ying Song; Bailey H Baumann; Rebecca J Kapphahn; Sandra R Montezuma; Deborah A Ferrington; Joshua L Dunaief
Journal:  Exp Eye Res       Date:  2019-05-31       Impact factor: 3.467

3.  Multimodal imaging characterization of peripheral drusen.

Authors:  Eleonora Corbelli; Enrico Borrelli; Mariacristina Parravano; Riccardo Sacconi; Marta Gilardi; Eliana Costanzo; Michele Cavalleri; Lea Querques; Francesco Bandello; Giuseppe Querques
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-03       Impact factor: 3.117

4.  Retinal phenotyping of variants of Alzheimer's disease using ultra-widefield retinal images.

Authors:  Lajos Csincsik; Nicola Quinn; Keir X X Yong; Sebastian J Crutch; Tunde Peto; Imre Lengyel
Journal:  Alzheimers Dement (Amst)       Date:  2021-08-20

5.  CLINICAL CHARACTERIZATION OF STARGARDT DISEASE PATIENTS WITH THE p.N1868I ABCA4 MUTATION.

Authors:  Frederick T Collison; Winston Lee; Gerald A Fishman; Jason C Park; Jana Zernant; J Jason McAnany; Rando Allikmets
Journal:  Retina       Date:  2019-12       Impact factor: 4.256

6.  Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration.

Authors:  Hikari Taniguchi; Izumi Yoshida; Masashi Sakamoto; Takatoshi Maeno
Journal:  BMC Ophthalmol       Date:  2021-04-28       Impact factor: 2.209

7.  Assessing the Clinical Utility of Expanded Macular OCTs Using Machine Learning.

Authors:  Andrew C Lin; Cecilia S Lee; Marian Blazes; Aaron Y Lee; Michael B Gorin
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

8.  CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation.

Authors:  Demetrios G Vavvas; Kent W Small; Carl C Awh; Brent W Zanke; Robert J Tibshirani; Rafal Kustra
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

9.  Novel grid combined with peripheral distortion correction for ultra-widefield image grading of age-related macular degeneration.

Authors:  Patrick Oellers; Inês Laíns; Steven Mach; Shady Garas; Ivana K Kim; Demetrios G Vavvas; Joan W Miller; Deeba Husain; John B Miller
Journal:  Clin Ophthalmol       Date:  2017-11-08

10.  Quantitative Comparison of Fundus Images by 2 Ultra-Widefield Fundus Cameras.

Authors:  Andrew Chen; Suveera Dang; Mina M Chung; Rajeev S Ramchandran; Angela P Bessette; David A DiLoreto; David M Kleinman; Jayanth Sridhar; Charles C Wykoff; Ajay E Kuriyan
Journal:  Ophthalmol Retina       Date:  2020-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.